Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes.
axial spondyloarthritis
cardiovascular risk factors
disease activity
psoriatic arthritis
quality of life
smoking
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
10 Jan 2023
10 Jan 2023
Historique:
received:
20
11
2022
revised:
30
12
2022
accepted:
06
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
The effect of smoking on disease activity and quality of life (QoL) in spondyloarthritis (SpA) is far from clear. We aimed to evaluate the relationship between smoking and these outcomes in patients with axial SpA (axSpA) and psoriatic arthritis (PsA). This cross-sectional observational multicenter study included 242 patients with axSpA and 90 with PsA. The association between conventional cardiovascular risk factors and disease activity as well as QoL, in both SpA phenotypes was evaluated. For this, univariate and multivariate regression analyses were performed, as well as confirmatory meta-analyses. Regardless of age, sex, or disease duration, patients with axSpA showed significantly less association with obesity (OR 0.50 (0.26-0.96), Although the cardiometabolic risk profile is clearly different between both SpA phenotypes, the only clear link between these factors and increased disease activity was observed between smoking and axSpA. Our findings need further confirmation.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The effect of smoking on disease activity and quality of life (QoL) in spondyloarthritis (SpA) is far from clear. We aimed to evaluate the relationship between smoking and these outcomes in patients with axial SpA (axSpA) and psoriatic arthritis (PsA).
PATIENTS AND METHODS
METHODS
This cross-sectional observational multicenter study included 242 patients with axSpA and 90 with PsA. The association between conventional cardiovascular risk factors and disease activity as well as QoL, in both SpA phenotypes was evaluated. For this, univariate and multivariate regression analyses were performed, as well as confirmatory meta-analyses.
RESULTS
RESULTS
Regardless of age, sex, or disease duration, patients with axSpA showed significantly less association with obesity (OR 0.50 (0.26-0.96),
CONCLUSIONS
CONCLUSIONS
Although the cardiometabolic risk profile is clearly different between both SpA phenotypes, the only clear link between these factors and increased disease activity was observed between smoking and axSpA. Our findings need further confirmation.
Identifiants
pubmed: 36675480
pii: jcm12020551
doi: 10.3390/jcm12020551
pmc: PMC9865976
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Reumatol Clin (Engl Ed). 2018 Jul - Aug;14(4):207-210
pubmed: 28262478
Rheumatology (Oxford). 2020 Jul 1;59(7):1472-1481
pubmed: 32236486
Ann Rheum Dis. 2014 Jun;73(6):1012-9
pubmed: 24790067
Drugs Aging. 2020 Feb;37(2):99-104
pubmed: 31745833
Arthritis Res Ther. 2018 Jul 27;20(1):156
pubmed: 30053895
Semin Arthritis Rheum. 2017 Dec;47(3):351-360
pubmed: 28802776
Rheumatol Int. 2017 Feb;37(2):239-244
pubmed: 27815702
Ann Rheum Dis. 2016 Mar;75(3):532-9
pubmed: 25667205
Front Med (Lausanne). 2018 Mar 12;5:62
pubmed: 29594122
Arthritis Care Res (Hoboken). 2017 Oct;69(10):1606-1611
pubmed: 27998026
RMD Open. 2015 Sep 14;1(1):e000153
pubmed: 26535153
Clin Rheumatol. 2019 Jan;38(1):3-10
pubmed: 30338414
Curr Opin Rheumatol. 2019 Mar;31(2):109-117
pubmed: 30624284
Rheumatol Ther. 2017 Dec;4(2):219-231
pubmed: 28600789
Rheumatology (Oxford). 2021 Mar 2;60(3):1465-1473
pubmed: 33011808
Front Med (Lausanne). 2021 May 26;8:679009
pubmed: 34124110
Best Pract Res Clin Rheumatol. 2018 Jun;32(3):369-389
pubmed: 31171309
Lancet. 2011 Jun 18;377(9783):2127-37
pubmed: 21684383
J Rheumatol. 2022 Jan;49(1):36-43
pubmed: 34266987
J Rheumatol. 2020 Oct 1;47(10):1483-1489
pubmed: 32358161
Clin Rheumatol. 2018 Mar;37(3):661-666
pubmed: 29380165
Rheum Dis Clin North Am. 2009 Nov;35(4):819-27, x
pubmed: 19962626
Curr Rheumatol Rep. 2019 Mar 12;21(5):19
pubmed: 30868287
J Rheumatol. 2022 Jan;49(1):8-15
pubmed: 34393105
Expert Rev Clin Immunol. 2018 May;14(5):405-417
pubmed: 29681202
Int J Mol Sci. 2020 Mar 01;21(5):
pubmed: 32121574
Am J Health Behav. 2008 Jan-Feb;32(1):93-110
pubmed: 18021037